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Abstract 
Glioblastoma multiform carries a dismal prognosis with poor response to gold standard 
treatment. Innovative data analysis methods have been developed to characterize tumor 
genomic expression with histologic features. In a clinical setting, biopsy selection methods may 
be constrained by time and financial burden to the patient. Thus, we investigate the impact 
biopsy selection has on correlation between prognostic and histologic features in 35 patients 
with GBM. We compared methods using limited volumes, moderate volumes, and enblock 
tumor volumes. Additionally, we investigated the impact of random versus strategic methods 
for limited and moderate volume biopsies. Finally, we compared correlation results by selecting 
one to five small biopsy. We observed a wide range in correlation significance across selection 
methods. These findings may aid clinical management of GBM and direct better biopsy 
selection necessary for the development and deployment of targeted therapies.   
Introduction 
Glioblastoma multiform (GBM) is the most common and worst form of glioma in terms of 
therapeutic response, aggressiveness, and prognosis. The treatment gold standard for GBM 
includes surgical resection, chemotherapy, and radiotherapy, which is invasive, has unwanted 
side effects, and can have a large negative impact on quality of life. Even with the efforts of 
gold standard treatment, tumor recurrence is very high compared to other neoplasms1. Thus, 
efforts have been made to characterize the molecular and genetic profile within GBM so 
targeted therapeutic methods could be used with a more effective clinical approach2,3. 
Recently, Ivy Glioblastoma Atlas Project (Ivy GAP) initiated a several studies to evaluate 
genetic expression associated with histologic and clinical features4,5. Cantanhede and Oliveira 
observed that within histologic features there are significant variations between platelet 
derived growth factor (PDGR) family genes. Additionally, they found significant differences in 
expression between left and right lobes.  Similarly, Puchalski et al observed that RNA-seq had 
significant variation across histologic structural features defined as cellular tumor, leading edge, 
palisading necrosis, and microvascular proliferation. These works demonstrate with statistical 
confidence a link between histologic structural features and genetic expression.  
In a clinical setting, the diagnostic gold standard is medical imaging, preferably magnetic 
resonance imaging (MRI), followed by biopsy confirmation. Biopsy tissue volume may vary 
across cases from needle biopsy to biopsy sectioning during resection. In either case, the tissue 
sampling is likely less than the average volume per patient, 7 cm3, used by Ivy GAP. Since a GBM 
hallmark is intratumor heterogeneity, we hypothesized that biopsy features would vary greatly 
between methods.  
Methods 
Data selection.  
Histologic features, clinical and genomic data for 35 of 41 available GBM patients was 
retrospective obtained from the Ivy GAP repository (Allen Institute for Brain Science. Ivy 
Glioblastoma Atlas Project. Available from: https://glioblastoma.alleninstitute.org/). The cohort 
was selected based on the following inclusion criteria: enbloc resection contains at least three 
sub blocks; and complete prognosis data. Histologic feature data was acquired from Ivy GAP 
(Allen Institute for Brain Science. Ivy Glioblastoma Atlas Project. Available from: 
https://glioblastoma.alleninstitute.org/static/download.html). The histologic features defined 
by Ivy GAP (SOURCE) are: leading edge (LE); hyperplastic blood vessels in leading edge (LEhbv); 
infiltrating tumor (IT); hyperplastic blood vessels in infiltrating tumor (IThbv); cellular tumor 
(CT); perinecrotic zone (CTpnz); psuedopalisading cells but no visible necrosis (CTpnn); 
pseudopalisading cells around necrosis (CTpan); hyperplastic blood vesselsin cellular tumor 
(CThbv); microvascular proliferation (CTmvp); and necrosis (CTne). Histologic features were 
normalized to the total H&E tissue area for each slide. Clinical and genomic data was acquired 
from Ivy GAP (Allen Institute for Brain Science. Ivy Glioblastoma Atlas Project. Available from: 
https://glioblastoma.alleninstitute.org/static/download.html) and tabulated for the selected 
cohort. 
Data analysis. 
From the compiled data, we analyzed seven biopsy selection methods in MATLAB R2018b 
(www.mathworks.com). Three location methods (random, tumor center, and max necrosis) 
were applied to two volume methods (slide and block), resulting in the following six 
combinations: (A) randomly select one slide; (B) randomly select one block average; (C) one 
slide at tumor centroid; (D) one block average at tumor centroid; (E) one slide at necrosis; and 
(F) one block average at necrosis. We selected slide and block volumes to represent needle 
biopsy (NB) and surgical biopsy (SB) volumes respectively. The last method was (G) the enbloc 
average, representing the max tissue volume of data available for a patient. For methods C and 
E, if the location of interest contained more than one slide, a slide was chosen at random. For 
methods B, D, and F all the slides from the corresponding block were averaged together. For 
biopsy number analysis, we randomly selected one to five slides from unique block locations 
across each tumor. Correlation between un-censored, continuous variables overall survival 
(OS), progression free survival (PFS) and histologic features were evaluated by Pearson’s 
correlation. Correlations were considered statistically significant if p value<0.10.  
Results 
Clinical and genomic data for cohort. 
Information from the compiled data as summarized in Table 1 reveals that the cohort has a 
young age at the time of diagnosis and comparable gender distribution. For gross primary 
tumor locations, the right frontal lobe has the highest incident, followed by left parietal and 
mixed right hemisphere. The cohort has high functioning Karnofsky Performance Status (KPS), 
with nearly half presenting neurologic defect, indicating mildly impaired quality of life and 
favorable prognosis (SOURCE 10,11,12). However, as common with GBM, the prognostic 
outcomes for the cohort are poor with median progression free survival (PFS) of 107 days, and 
median overall survival (OS) of 439 days. For genomic expression, Isocitrate Dehydrogenase 1 
(IDH1) mutation is observed in three patients, consistent with the literature (SOURCE). 
Clinical Data 
Gender 
Female N=17 48.57% 
Male N=18 51.43% 
Age At Diagnosis (years) 
Mean ± standard deviation 58.7 ±12.0  
Median 61  
Karnofsky Performance Status 
Mean ± standard deviation 88 ±10.5  
>70 N=29 82.86% 
≤70 N=6 17.14% 
History of Seizure 
Present N=10 28.57% 
Not-present N=25 71.43% 
Neurologic defect 
Present N=16 45.71% 
Not-present N=19 54.29% 
Primary Tumor Location 
Left frontal N=1 2.86% 
Left Occipital N=1 2.86% 
Left Parietal N=6 17.14% 
Left Temporal N=5 14.29% 
Right Frontal N=7 20.00% 
Right Parietal N=4 11.43% 
Right Temporal N=5 14.29% 
Mixed Right Hemisphere N=6 17.14% 
Progression free survival (days) 
Mean ± standard deviation 205.5 ±256.8  
Median 107  
Overall survival (days) 
Mean ± standard deviation 491.4 ±321.5  
Median 439.5  
Genomic Data 
PTEN 
Deletion/Loss N=18 51.43% 
Gain N=3 8.57% 
Normal N=3 8.57% 
IDH1 
Wild-type N=30 85.71% 
Mutated N=3 8.57% 
1p19q Deletion 
Positive N=3 8.57% 
Negative/Normal N=21 60.00% 
MGMT PCR 
Methylated N=6 17.14% 
Unmethylated N=19 54.29% 
 
Table 1. Clinical and genomic data for research cohort. PTEN: Phosphatase and Tensin Homolog; 
IDH1: Isocitrate Dehydrogenase 1; MGMT: O-6-Methylguanine-DNA Methyltransferase; PCR: 
Polymerase chain reaction. 
Correlation between overall survival and histologic feature vary by biopsy method. 
Correlation significance between overall survival (OS) and LE, IT, CTpnz, CTpnn, CTmvp, CTne 
vary by biopsy method as shown in Figure 1. The correlation between OS and LE is significant 
for NB methods taken at random and at max necrosis (p=0.05, and p=0.09 respectively). For IT, 
correlation with OS is significant for NB method taken from max necrosis (p=0.08). The 
correlation between CTpnz and OS is significant for NB methods taken at random and from max 
necrosis (p=0.05 and 0.07 respectively). For CTpnn, the correlation is significant for SB methods 
taken at random and at tumor centroid (p=0.008, 0.02 respectively), while for NB method it is 
significant taken from tumor center (p=0.002). Histologic feature CTmvp has significant 
correlation with OS for SB methods taken at max necrosis and enblock (p=0.06, and 0.006 
respectively). For OS and CTne SB at max necrosis has significant correlation (p=0.04). The 
correlation between OS and NB, SB, and enbloc is shown in Figure 1 A, C, and E respectively. 
Correlation between progression free survival and histologic feature vary by biopsy method.  
The correlation between progression free survival (PFS) and histologic features CTpnn and 
CTmvp vary based on biopsy method as shown in Figure 1. For SB based methods, the 
correlation between PFS and CTpnn is significant if the biopsy is taken from the center 
(p=0.007). The correlation between PFS and CTmvp is significant if NB biopsy from the tumor 
center or SB from random is used (p=0.03, and p=0.035 respectively). The correlation between 
PFS and NB, SB, and enbloc is shown in Figure 1 B, D, and E respectively. 
 
 
 Figure 1: Correlation between prognosis and structural features across biopsy methods. (A) 
Correlation between overall survival (OS) and histology structural features by limited volume, 
needle biopsy (NB) like methods. (B) Correlation between progression free survival (PFS) and 
histology structural features by limited volume, needle biopsy (NB) like methods. (C) Overall 
survival (OS) correlation to histologic structural features using a larger volume, surgical biopsy 
(SB) like methods. (D) Progression free survival (PFS) correlation to histologic structural features 
using a larger volume, surgical biopsy (SB) like methods. (E) Correlation between prognostic 
factors and histologic structural features using enblock method. 
Correlation between prognosis and histologic feature vary by the number of biopsies 
selected.  
For correlation between PFS and histologic feature CTpnz (p=0.036) there was significant 
variation from the number of biopsies. For correlation between OS and histologic features LE 
(p=0.026), LEhbv (p=0.011), and CTmvp (p=0.003) there was significant variation from the 
number of biopsies. Variation in correlation between prognosis and histologic features due to 
the number of biopsies can be observed in Figure 2. 
 
 
Figure 2. Variation in correlation between prognosis and histology based on the number of 
biopsies taken. PFS: progression free survival; OS: overall survival. 
Discussion 
This study presents the impact of biopsy selection method on correlation between prognosis 
and histologic features. The impact of intra-tumoral heterogeneity can be observed in the 
correlation range by method. Between needle like biopsy, surgical biopsy, and enblock analysis, 
correlation with prognosis varies greatly.  
GBM has been studied widely, however to our knowledge, this is the first study to look at the 
effects of sampling technique form in-vivo data. Repositories, such as The Cancer Genome Atlas 
(TCGA) have clinical, genomic, and biopsy data, however the location of biopsy relative to the 
tumor is unknown. Additionally, the biopsies volume used to derive histologic features 
characteristic of GBM6,7, such as the presence of necrosis or palisading tumor, is unknown. 
However, multiple studies have linked, or argue such, that a relationship between histologic 
features and genomic expression and/or imaging features are reliable 8,9.  
Based on this analysis, we can observe vast variation in correlation between limited volume 
biopsies, such as needle biopsy. Between one and three samples there is a wide shift in 
correlation, consistent with intra-tumoral heterogeneity. Additionally, a plateau is observed in 
limited volume biopsies between three and five samples, this appears consistent with the 
observation between random, tumor center, and necrotic core for limited volume biopsy. 
However, when moving to mid volume or max volume observed, methods B, D, F, and G, few 
correlations between OS or PFS and histologic features are significant. This appears to 
represent a “wash-out” like effect, where the heterogeneity across the tumor is no longer 
observed. Considering the presented data, select limited volume biopsy, such as needle biopsy, 
across the tumor has the most robust correlation with prognostic factors OS and PFS. Clinically, 
these methods may be applied to robustly capture histologic features consistent with GBM. 
Three to five limited volume biopsies taken from the tumor center, max necrosis, and randomly 
at a minimum of 1 cm separation results in strong correlation to prognostic features.  
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